dupix approv asthma eosinophil phenotyp
eosinophil phenotyp cover market eosinophil count cells/ul
fda approv dupix moderate-to-sever asthma patient year
older specif either depend oral corticosteroid
eosinophil phenotyp think give access bulk market
eosinophil phenotyp like refer patient eosinophil count cells/ul
repres major patient clinic trial blood analysi like
requir physician prescrib dupix also requir biolog
ultim see dupix prefer biolog patient exhaust
inhal option possibl oral corticosteroid case
dose home improv advantag xolair other
importantli dupix administ home initi physician instruct
signific advantag vs xolair biolog aid commerci
uptak also dupix show statist signific improv lung function
character wherea xolair advantag dupix
posit drug prefer biolog may also help take share oral
conserv estim peak sale dupix asthma
base modifi dupix asthma project expect total peak sale
total peak sale us expect
eu project assum
uncontrol moderate-to-sever asthma patient would cells/ul eosinophil
maintain hold rate price target encourag
dupix approv moderate-to-sever asthma overal develop
maintain view need focu develop asset would
provid full econom compani
price close busi octob
biotech discov
invent manufactur commerci medicin
treat seriou diseas
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
fy asthma us marketdiagnos asthmat moderate/sever asthma asthma uncontrol mod/sever asthma eosinophil eosinophil mod/sever asthma patient w/ eosinophil laba mod/sever asthma laba ic w/ eosinophil fail laba mod/sever asthma fail laba ic w/ eosinophil uncontrol mod/sever asthma pt w/ eosinophil uncontrol mod/sever asthma pt w/ eosinophil dupilumab patients- per dose per per annual cost per revenu per us dupilumab demand uncontrol mod/sever asthma- discount rebates- build drawdown us dupilumab revenu uncontrol mod/sever asthma- figur eu uncontrol persist asthma market project
fy asthma eu marketdiagnos asthmat moderate/sever asthma asthma uncontrol mod/sever asthma eosinophil eosinophil mod/sever asthma patient w/ eosinophil laba mod/sever asthma fail laba mod/sever asthma fail laba ic w/ eosinophil uncontrol mod/sever asthma pt w/ eosinophil uncontrol mod/sever asthma pt w/ eosinophil dupilumab patients- per annual cost per revenu per inventori build drawdown discount rebates- eu dupilumab revenu uncontrol mod/sever asthma- figur upcom expect catalyst
oct ph studi osteoarthritisfda decis bla advanc csccdata ph polypsregulatori ex-u regulatori agenc decis applic adult atop dermat regulatori investig new drug applic ind antibodyfda regulatori submiss npdr non-dm patientsregulatori sbla expand indic adolesc year age atop dermatitisdata ph one-year data panorama trial npdr innon-dm patient figur valuat dcf
regeneron dcf valuat free yoy depreci less capit less work capit free firm yoy discount rate pv termin net outstand valu per equityrisk-fre growth ratewacctermin growth ratetvdiscount rate figur valuat price-to-earnings
fy producteyleau ex-u arcalystu ex-u revenues- net product sale book praluentu ex-u ww zaltrap- ww kevzara- us revenu probabl adjust ex-u revenu probabl adjust dupixent- us atop uncontrol asthma- ex-u atop uncontrol asthma- figur incom statement
detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose
contact inform appear front page report
incom bayer collabor technolog net product contract research other- total good option expensegross oper expensesresearch sanofi bayer option non-reimburs sell gener option sg collabor total oper profit loss oper profit loss incom expens incom expens loss earli extinguish debtpre-tax incom pre-tax incom tax rate tax expens benefit tax rate tax expens benefit net incom loss interest expens convert debtnon-cash interest relat convert senior notesadjust net net incom loss ep fulli ep fulli share dilut share outstand dilut share outstand regeneron pharmaceut
